Exenatide · source year
5 selected, source-linked Exenatide records carrying a 2012 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
3 represented types.
5 distinct public records.
Cited chronology
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 22753275 at 2026-07-30T22:15:26.545Z. PubMed recorded a metadata revision date of 2012-08-23 and an Entrez history date of 2012-07-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01056549 at 2026-07-30T22:14:20.917Z. Its registry update date was 2012-06-22, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01580514 at 2026-07-30T22:14:20.913Z. Its registry update date was 2012-04-19, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 20436114 at 2026-07-30T22:15:26.497Z. PubMed recorded a metadata revision date of 2012-02-09 and an Entrez history date of 2010-05-04. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 022200 with status AP dated 2012-01-27, and names exenatide synthetic among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗